RxDoctor Payments Data

Chaim Moeller, MD

Clinical Cardiac Electrophysiology · Kew Gardens, NYNPI 1306016969

Payments from drug & device makers

$5,241in general payments, 2019–2025

Across 230 payments — averaging $22.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$932
  • Novartis$448
  • Merck$411
  • Kestra Medical Technology Services, Inc.$395
  • Amgen$344
  • Biotronik Inc.$327
  • plus $2K from 26 others

What the payments were for

  • Travel & lodging$1653%
  • Food & beverage$5,07597%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,241 in reported general payments places this provider in the 20th percentile of 214 clinical cardiac electrophysiology providers in New York.

See all clinical cardiac electrophysiology providers in New York

Medicare billing

Part B allowed, 2024
$215,911
Medicare patients
358
Services billed
2,292

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan276$263,272
EliquisApixaban185$201,449
JardianceEmpagliflozin150$128,651
XareltoRivaroxaban118$98,558
MultaqDronedarone Hcl36$34,737
FarxigaDapagliflozin Propanediol23$20,787
BrilintaTicagrelor19$11,350
Metoprolol Succinate384$4,480
Atorvastatin Calcium154$1,760
Amiodarone Hcl34$1,724
Rosuvastatin Calcium118$1,584
Losartan Potassium178$1,184
Chlorthalidone64$1,027
Carvedilol142$996
Ranolazine ErRanolazine26$749

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$448$263,272276 claims
PfizerEliquis$100$201,449185 claims
Boehringer IngelheimJardiance$326$128,651150 claims
Johnson & JohnsonXarelto$932$98,558118 claims
AstraZenecaFarxiga, Brilinta$104$32,13742 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 214 clinical cardiac electrophysiology providers in New York.

Other clinical cardiac electrophysiology in Kew Gardens

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →